



REFERENCES

- A Guide to Calculating the Lung Allocation Score.
http://www.unos.org/SharedContentDocuments/lung_allocation_score_updated_01072009.pdf. Accessed October 2009.
- AcidRefluxConnection.com. <http://www.healthcentral.com/acid-reflux/?ic=1102>. Accessed October 2009.
- Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. *Chest*. 2007;131:1448-1453.
- Allam JS, Kootom TJ, Vuk-Pavlovic Z, Limper AH. Biomarkers in idiopathic pulmonary fibrosis: a lung tissue research consortium based study. Poster presented at: 2008 ATS Annual Meeting; May 18, 2008; Toronto, Canada.
- Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. *Eur Resp J*. 2003;22:821-826.
- American College of Gastroenterology (ACG). <http://www.acg.gi.org/>. Accessed October 2009.
- American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). *Am J Respir Crit Care Med*. 2000;161:646-664.
- American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. *Am J Respir Crit Care Med*. 2002;165:277-304.
- Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. *N Engl J Med*. 2007;356:1317-1326.
- Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. *Radiology*. 2008;246:935-940.
- Clark M, Singh S, Cooper A, Carr A, Hubbard R. A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. *Thorax*. 2001;56:482-486.
- Clinical trials.gov. <http://www.clinicaltrials.gov/ct2/results?term=ipf>. Accessed October 2009.
- Clinical trials as a treatment option for IPF.
<http://www.pilotforipf.org/resources/PILOTPamphlet1.pdf>. Accessed October 2009.
- Cormick W, Olson LG, Hensley MJ, Saunders NA. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. *Thorax*. 1986;41:846-854.
- Cronkhite, JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2008;178:729-737.
- Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. *N Engl J Med*. 2005;353:2229-2242.
- DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med*. 2000;160:2101-2107.
- Douglas NJ, Flenley DC. Breathing during sleep in patients with obstructive lung disease. *Am Rev Respir Dis*. 1990;141:1055-1070.
- Ebell MH. Routine screening for depression, alcohol problems, and domestic violence. *Am Fam Physician*. 2004;69:2421-2422.
- Emotional Well-Being. http://www.pilotforipf.org/resources/PtCounseling_01.pdf. Accessed October 2009.
- Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. *Thorax*. 2003;58:143-148.
- Froese AR, Moeller A, Ask K, Gauldie J, Kolb M. Markers of disease activity and lung function in UIP: collagen turnover products. Poster presented at: 2008 ATS Annual Meeting; May 18, 2008; Toronto, Canada.
- GOLD Guidelines 2008.
<http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2003>. Accessed October 2009.
- Greene KE, King TE, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. *Eur Respir J*. 2002;19:439-446.
- Greider CW, Blackburn EH. Telomeres, telomerase and cancer. *Scientific American*. 1996;274(2):92-96.
- Hertz MI, Aurora P, Christie JD, et al. Registry of the International Society for Heart and Lung Transplantation: a quarter century of thoracic transplantation. *J Heart Lung Transplant*. 2008;27:937-942.



- Hiwatari N, Shimura S, Yamauchi K, Nara M, Hida W, Shirato K. Significance of elevated procollagen-III-peptide and transforming growth factor-beta levels of bronchoalveolar lavage fluids from idiopathic pulmonary fibrosis. *Tohoku J Exp Med.* 1997;181(2):285-95.
- Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. *Thorax.* 2008;63:549-554.
- Jackson RM, Ramos CF, Glassberg M, Bejarano P, Gomez-Marin O. Effects of sildenafil on exercise and dyspnea in IPF patients. *Am J Respir Crit Care Med.* 2009;179:A1134.
- Jorenby DE. Smoking cessation strategies for the 21st century. *Circulation.* 2001;104:E51-E52.
- Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. *Chest.* 2009;135:1557-1563.
- Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. *Am J Respir Crit Care Med.* 2003;168:1084-1090.
- Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. *Chest.* 2007;131:402-409.
- Lynch DA, Godwin JD, Safran S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. *Am J Respir Crit Care Med.* 2005;172:488-493.
- Medical Oxygen and Respiratory-Related Equipment. Condensed from TSA website. http://www.tsa.dhs.gov/travelers/airtravel/specialneeds/editorial_1374.shtm#2. Accessed October 2009.
- Mermigkis C, Stagaki E, Amfilochiou A, et al. Sleep quality and associated daytime consequences in patients with idiopathic pulmonary fibrosis. *Med Princ Pract.* 2009;18:10-15.
- Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2009;179:588-594.
- Nakamura M, Ogura T, Miyazawa N, et al. Outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) treated with sivelestat and the prognostic value of serum KL-6 and surfactant protein D. *Nihon Kokyuki Gakkai Zasshi.* 2007;45:455-459.
- Nathan SD, Noble PW, Tudor RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. *Am J Respir Crit Care Med.* 2007;175:875-880.
- National Digestive Diseases Information Clearinghouse. <http://digestive.niddk.nih.gov/ddiseases/pubs/gerd/>. Accessed October 2009.
- Noble PW, Homer RJ. Idiopathic pulmonary fibrosis: new insights into pathogenesis. *Clin Chest Med.* 2004;25:749-758.
- Noble P, Albera C, Bradford W, et al. The CAPACITY (CAP) trials: randomized, double-blind, placebo-controlled, phase III trials of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). *Am J Respir Crit Care Med.* 2009;179:A1129.
- Noble P, Albera C, Bradford W, et al. The CAPACITY (CAP) trials: randomized, double-blind, placebo-controlled, phase III trials of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). *Am J Respir Crit Care Med.* 2009;179:C98.
- Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant.* 2006;25:745-755.
- Patel S, Takahashi S, Demchuck C, Doeing D, Noth I, Strek ME. Gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2009;179:A4063.
- Physicians Desk Reference. [http://pdr.net/druginformation/DocumentSearchn.aspx?documentId=62950550&drugname=Chantix Tablets](http://pdr.net/druginformation/DocumentSearchn.aspx?documentId=62950550&drugname=Chantix%20Tablets). Accessed October 2009.
- Pulmonary rehabilitation: maximizing function. 2007. http://www.pilotforipf.org/resources/PtCounseling_07.pdf. Accessed October 2009.
- Raghu G, Chang J. Idiopathic pulmonary fibrosis: current trends in management. *Clin Chest Med.* 2004;25:621-636.
- Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2006;174:810-816.
- Raghu G, Freudemberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. *Eur Respir J.* 2006;27(1):136-142.
- Randomized, placebo-controlled study to evaluate safety and effectiveness of ambrisentan in IPF (ARTEMIS). <http://clinicaltrials.gov/ct2/show/NCT00768300>. Accessed October 2009.
- Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. *PLoS Med.* 2008;5(4):e93.



Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. *J Intern Med.* 2006;260:429-434.

Schaberg T, Orzechowski K, Oesterling C, Lode H, Schuppan D. Simultaneous measurement of collagen type-VI-related antigen and procollagen type-III-N-propeptide levels in bronchoalveolar lavage. *Eur Respir J.* 1994;7:1221-1226.

Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 1998;157(6 Pt 1):1791-1797.

Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP 3rd. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. *Drugs.* 2004;64:405-430.

Shlobin OA, Edwards E, Nathan SD. Waiting times and mortality for IPF patients listed for bilateral or single lung transplantation. *J Heart Lung Transplant.* 2009;28:S168.

Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. *Respir Med.* 2009;103:180-186.

Strollo DC. Imaging of idiopathic interstitial lung diseases. Concepts and conundrums. *Am J Respir Cell Mol Biol.* 2003;29(3 Suppl):S10-S18.

Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. *Am J Respir Crit Care Med.* 2008;177:433-439.

Swigris JJ, Brown KK, Make BJ, Wamboldt FS. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. *Respir Med.* 2008;102:1675-1680.

Swigris JJ, Swick J, Wamboldt FS, Kervitsky D, Brown KK. Heart rate recovery (HRR) after 6MWT predicts survival in IPF. *Am J Respir Crit Care Med.* 2009;179:A1122.

Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. *Am J Respir Crit Care Med.* 2000;162:1109-1114.

Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ. Mechanisms of pulmonary fibrosis. *Annu Rev Med.* 2004;55:395-417.

Thannickal VJ, Lloyd JE. Idiopathic pulmonary fibrosis: a disorder of lung regeneration? *Am J Respir Crit Care Med.* 2008;178:663-665.

Transportation Security Administration.
http://www.tsa.dhs.gov/travelers/airtravel/specialneeds/editorial_1374.shtm#2.
Accessed October 2009.

Walter N, Collard HR, King TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis. *Proc Am Thorac Soc.* 2006;3:330-338.

Yokiyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. *Respirology.* 2006;11:164-168.

Yokoyama A, Kohno N, Hamada H, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 1998;158:1680-1684.

Zisman DA, Kawut SM, Lederer DJ, et al. Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia. *Chest.* 2009;135:929-935.